Ab00449-1.4 Anti-alpha 5 beta 1 Integrin [M200 (Volociximab)]
Description: Recombinant monoclonal antibody to alpha 5 beta 1 Integrin. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma M200 (Volociximab). This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding of Fc Receptor and complement.
Clone Number: M200 (Volociximab)
UniProt Accession Number of Target Protein: P08648
Alternative Name(s) of Target: Fibronectin receptor; CD49 antigen-like family member E; Integrin alpha-F; VLA-5; CD49e.
Published Application(s): ELISA; FC; IF; Block; IHC
Published Species Reactivity: Human
Immunogen: Heterodimeric a5ß1Fc fusion protein
Specificity: The antibody binds to human α5β1 integrin with a Kd of 0.367 nM (determined by Biacore), an EC50 of 0.2 nM and an IC50 of 2.3 nM.
Application Notes: The antibody binds specifically to α5β1 integrin, which is part of the superfamily of glycoprotein transmembrane receptors for ligands such as fibronectin, vitronectin, laminins and collagens. The α5β1 integrin receptor plays a key role in cellular processes such as inflammation, cell proliferation, angiogenesis and tumour metastasis. Comprising the variable domain of the original mouse antibody, a chimeric mouse:human IgG4 version of this antibody has been tested in vivo: In cynomolgus monkeys with laser-induced choroidal neovascularization (CNV), in rabbit models and in human volunteers. The antibody reached Phase II clinical trials with PDL Biopharma and Biogen-Idec.
Antibody First Published in:
Ramakrishnan et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86. PMID:17024968 Note on publication: Describes the role of α5β1 integrin in the progression of angiogenesis, and the generation of Volociximab, a chimeric monoclonal antibody whose in vitro and in vivo use is evaluated for therapeutic use.
Supplied in: PBS with preservative (0.02% Proclin 300)
Storage Recommendation: Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C
Concentration: See vial label.
NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.
Species and Isotype: Mouse IgG1, Fc Silent™, kappaClone Number: M200 (Volociximab)
UniProt Accession Number of Target Protein: P08648
Alternative Name(s) of Target: Fibronectin receptor; CD49 antigen-like family member E; Integrin alpha-F; VLA-5; CD49e.
Published Application(s): ELISA; FC; IF; Block; IHC
Published Species Reactivity: Human
Immunogen: Heterodimeric a5ß1Fc fusion protein
Specificity: The antibody binds to human α5β1 integrin with a Kd of 0.367 nM (determined by Biacore), an EC50 of 0.2 nM and an IC50 of 2.3 nM.
Application Notes: The antibody binds specifically to α5β1 integrin, which is part of the superfamily of glycoprotein transmembrane receptors for ligands such as fibronectin, vitronectin, laminins and collagens. The α5β1 integrin receptor plays a key role in cellular processes such as inflammation, cell proliferation, angiogenesis and tumour metastasis. Comprising the variable domain of the original mouse antibody, a chimeric mouse:human IgG4 version of this antibody has been tested in vivo: In cynomolgus monkeys with laser-induced choroidal neovascularization (CNV), in rabbit models and in human volunteers. The antibody reached Phase II clinical trials with PDL Biopharma and Biogen-Idec.
Antibody First Published in:
Ramakrishnan et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86. PMID:17024968 Note on publication: Describes the role of α5β1 integrin in the progression of angiogenesis, and the generation of Volociximab, a chimeric monoclonal antibody whose in vitro and in vivo use is evaluated for therapeutic use.
Product Form
Purification: Protein A affinity purifiedSupplied in: PBS with preservative (0.02% Proclin 300)
Storage Recommendation: Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C
Concentration: See vial label.
Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic
procedures for humans or animals.
2162
